Capricor Therapeutics share price logo

Capricor Therapeutics

NASDAQ: CAPR

Small Cap

$7.24

+0.86

(+13.48%)

as on

Capricor Therapeutics Stock Performance

as on November 3, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $6.67
    $7.46
    downward going graph

    7.87%

    Downside

    3.04%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $2.96
    $40.37
    downward going graph

    59.12%

    Downside

    457.60%

    Upside

    downward going graph

Capricor Therapeutics share price movements today

Previous Close
$6.38
Open
$6.82
Volume
4.4M
Market Cap
$370.9M
Day's Low - High
$6.67 - $7.46
52 Week Low - High
$2.96 - $40.37

Capricor Therapeutics Historical Returns

1 Month Return
-19.11 %
3 Month Return
+ 72.38 %
1 Year Return
+ 19.28 %
3 Year Return
+ 152.26 %
5 Year Return
+ 87.56 %

Capricor Therapeutics Stock Fundamentals & Key Indicators

Check Capricor Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$370.9M

EPS (TTM)

-2.45

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.6

Industry PE ratio

-7.24

PEG Ratio

0.07

EBITDA

1.2B

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-56.60%

Capricor Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Capricor Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$370.9M87.56%-2.600.00%0.00%
Neutral$88.5B-36.16%-27.78-12.57%0.00%
StrongBuy$141.7B192.56%32.2786.04%0.00%
Buy$95.5B47.41%19.7685.77%0.40%

Stock Returns calculator for Capricor Therapeutics Stock including INR - Dollar returns

The Capricor Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Capricor Therapeutics investment value today

Current value as on today

₹1,27,578

Returns

₹27,578

(+27.58%)

Returns from Capricor Therapeutics Stock

₹19,275 (+19.28%)

Dollar Impact

₹8,303 (+8.3%)

Analyst Recommendation on Capricor Therapeutics Stock

Based on 6 analysts

BUY

66.67%

Buy

33.33%

Hold

0.00%

Sell

Based on 6 analysts, 66.66666666666666% of analysts recommend a 'BUY' rating for Capricor Therapeutics. Average target price of $27

Capricor Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Capricor Therapeutics.

What analysts predicted

73.19%UPSIDE

Target Price

$27

Current Price

$7.24

Analyzed by

6 Analysts

High

$54

Target

$27.00

Low

$21

Capricor Therapeutics target price $27, a slight upside of 73.19% compared to current price of $7.24. According to 6 analysts rating.

Indian Investors' Interest in Capricor Therapeutics Stock

Investment in Capricor Therapeutics Shares on INDmoney has dropped by -52.33% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-52.33% versus previous 30 day period

Search interest for Capricor Therapeutics Stock has decreased by -63% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-63% versus previous 30 day period

Capricor Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
4
3
2
11
-
-
-
-
-
-
Gross Profit
-6
-8
-9
-3
-18
-22
-20
-
-
-
Operating Income
-10
-11
-13
-7
-24
-27
-26
-29
-36
-42
EBITDA
-9
-10
-12
-6
-23
-25
-24
976
-33
255
Interest Expense
-
-
-
-
-
-
-
3
-
-
Depreciation
0
0
0
0
0
0
0
1,003
0
295
Income Before Tax
-9
-10
-12
-7
-24
-25
-24
-30
-33
-40
Income Tax Expense
-
-
-
-
-
-
-
-
-
0
Net Income
-9
-10
-12
-7
-24
-25
-24
-30
-33
-40
Net Profit Margin
-126.23%
-214.87%
-422.09%
-30.77%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Capricor Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
2
1
1
0
0
2
25
22
-
Gross Profit
2
1
-4
0
0
-19
-11
-27
-
Operating Income
-12
-15
-7
-13
-20
-29
-24
-42
-108
EBITDA
2
-15
-7
-13
-19
-28
-21
-39
-100
Interest Expense
0
-
-
-
-
-
-
-
3
Depreciation
0
0
0
0
0
0
1
1
1
Income Before Tax
2
-15
-7
-13
-20
-29
-22
-40
-105
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
2
-15
-7
-13
-20
-29
-22
-40
-105
Net Profit Margin
100.00%
100.00%
-411.61%
100.00%
100.00%
-755.07%
-44.76%
-124.37%
0.00%

Capricor Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-9
-10
-12
-7
-24
-25
-
-80,652
-33
-
Operating Cash Flow
-1
-12
-11
-14
-6
-20
-19
-23
-29
-31
Investing Cash Flow
-9
14
2
-123
23
14
15
43
-154
-48
Financing Cash Flow
2
2
67
81
0
0
0
248
1
-4
Change in Cash
-8
4
57
-57
17
-5
-3
268
-182
-84

Capricor Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
2
-15
-7
-13
-20
-29
-22
-40
-105
Operating Cash Flow
-14
-13
-6
-10
-16
4
-25
-39
-69
Investing Cash Flow
4
4
-3
5
-1
-35
5
-116
97
Financing Cash Flow
11
6
9
33
20
4
25
152
248
Change in Cash
2
-2
0
28
2
-25
5
-3
276

Global Institutional Holdings in Capricor Therapeutics

Check out the Institutions with significant holdings in Capricor Therapeutics.

Funds
Holdings
BlackRock, Inc.
7.13%
Vanguard
4.78%
VANGUARD INDEX FUNDS
3.86%
SPDR
3.55%
iShares
3.50%

Capricor Therapeutics News & Key Events

  • img

    Today's Timeline - 05 October

    Mon, 07:45 PM

    -

    Capricor announces positive open-label extension data for Deramiocel, showing significant reduction in upper limb loss in Duchenne muscular dystrophy patients.

Insights on Capricor Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 2.26M → 11.13M (in $), with an average increase of 79.7% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, CAPR stock has moved up by 18.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 184.8% return, outperforming this stock by 32.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 786.5% return, outperforming this stock by 767.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, -24.57M → -40.73M (in $), with an average decrease of 18.4% per quarter

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
OrganisationCapricor Therapeutics
Headquarters10865 Road to the Cure, San Diego, CA, 92121, US
IndustryBiotechnology
CEOLinda Marbán

Key Management of Capricor Therapeutics

Name

Title

Mr. Michael Maurer

Chief Commercial Officer

Nathaniel Hogan Ph.D.

Director of Biostatistics of Capricor Therapeutics

Dr. Linda Marbán Ph.D.

Co-Founder, President, CEO & Director

Mr. Anthony J. Bergmann M.B.A.

CFO & Corporate Treasurer

Ms. Karen G. Krasney Esq., J.D.

Executive VP, General Counsel & Secretary

Mr. Minghao Sun Ph.D.

Senior Vice President of Quality Control, Research & Product Development

Mr. Mark Awadalla

Chief Development Officer

Dr. Frank Isaac Litvack FACC, M.D.

Executive Chairman of the Board

Dr. Kristi A. H. Elliott Ph.D.

Chief Operating & Science Officer

Dr. Micheal Binks M.D.

Chief Medical Officer

FAQs

What is Capricor Therapeutics share price today?

Capricor Therapeutics share price today is $7.24 as on at the close of the market. Capricor Therapeutics share today touched a day high of $7.46 and a low of $6.67.

What is the 52 week high and 52 week low for Capricor Therapeutics share?

Capricor Therapeutics share touched a 52 week high of $40.37 on and a 52 week low of $2.96 on . Capricor Therapeutics stock price today i.e. is closed at $7.24,which is 82.07% down from its 52 week high and 144.59% up from its 52 week low.

What is Capricor Therapeutics's market capitalisation today?

Capricor Therapeutics market capitalisation is $0.00T as on .

How to invest in Capricor Therapeutics Stock (CAPR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Capricor Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Capricor Therapeutics Stock (CAPR) from India?

Indian investors can start investing in Capricor Therapeutics (CAPR) shares with as little as ₹94.9000015258789 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.00 in Capricor Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Capricor Therapeutics share’s latest price of $7.24 as on November 3, 2026 at 8:45 am IST, you will get 1.3812 shares of Capricor Therapeutics. Learn more about fractional shares .

What are the returns that Capricor Therapeutics has given to Indian investors in the last 5 years?

Capricor Therapeutics stock has given 87.56% share price returns and 27.07% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?